Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literatur zu Kapitel 6: Haarzell-Leukämie

Autor/en: Stefan Mahlmann
Letzte Änderung: 30.04.2011
  • Allsup DJ, Cawley JC.
    The diagnosis and treatment of hairy-cell leukaemia.
    Blood Rev 2002;16:255-262. PMID:12350368
    [Medline]


  • Au WY et al.
    Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience.
    Blood 1998;92:1160-1164. PMID:9694703
    [Medline]


  • Baer MR, Ozer H, Foon KA.
    Interferon-alpha therapy during pregnancy in chronic myelogenous leukemia and hairy cell leukemia.
    Br J hematol 1992;81:167-169. PMID:1643013
    [Medline]


  • Basso K et al.
    Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors.
    J Exp Med 2004;199:59-68. PMID:14707115
    [Medline]


  • Bastie JN et al.
    Five years follow-up after 2-chlorodeoxyadenosine treatment in thirty patients with hairy cell leukaemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
    Leuk Lymphoma 1999;35:555-565. PMID:10609793
    [Medline]


  • Berman E et al.
    Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon a-2b.
    Blood 1990;75:839-845. PMID:2302457
    [Medline]


  • Bernstein L, Newton P, Ross EK.
    Epidemiology of hairy cell leukemia in Los Angeles county.
    Cancer Res 1990;50:3605-3609. PMID:2340508
    [Medline]


  • Bouroncle BA, Wiseman BK, Doan CA.
    Leukemic reticuloendotheliosis.
    Blood 1958;13:609-630. PMID:13560561
    [Medline]


  • Brito-Babapulle V et al.
    The 14q+ marker in hairy cell leukemia: A cytogenetic study of 15 cases.
    Leukemia Res 1986;10:131-138. PMID:3485222
    [Medline]


  • Brito-Babapulle V et al.
    Chromosome abnormalities in hairy cell leukaemia variant.
    Genes Chromosomes Cancer 1994;10:197-202. PMID:7522043
    [Medline]


  • Brito-Babapulle V, Matutes E, Catovsky D.
    Cytogenetics, molecular genetics and immunophenotyping in hairy cell leukemia.
    In: Tallman MS, Polliack A (Eds).
    Hairy cell leukaemia, 49-63. Harwood Academic Publishers, New York, 2000


  • Burke JS.
    The value of bone-marrow biopsy in the diagnosis of hairy cell leukemia.
    Am J Clin Pathol 1978;70:876-884. PMID:727172
    [Medline]


  • Cassileth PA et al.
    Pentostatin induces durable remissions in hairy cell leukemia.
    J Clin Oncol 1991;9:243-246. PMID:1988572
    [Medline]


  • Catovsky D.
    Hairy cell leukemia and prolymphocytic leukaemia.
    Clin Haematol 1977;6:245-268. PMID:334414
    [Medline]


  • Catovsky D et al.
    Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia.
    Semin Oncol 1984;11:362-369. PMID:6594759
    [Medline]


  • Catovsky D, Quesada JR, Golomb HM.
    Guidelines for the treatment of hairy cell leukemia.
    Leukemia 1987;1:405-406. PMID:3312840
    [Medline]


  • Chadha P et al.
    Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.
    Blood 2005;106:241-246. PMID:15761021
    [Medline]


  • Chen YH et al.
    Immunophenotypic variations in hairy cell leukemia.
    Am J Clin Pathol 2006;125:251-259. PMID:16393677
    [Medline]


  • Cohen A et al.
    Deoxyadenosine triphospate as a potentially toxic metabolite in adenosine deaminase deficiency.
    Proc Natl Acad Sci USA 1978;75:472-476. PMID:272665
    [Medline]


  • Dearden CE et al.
    Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.
    Br J Haematol 1999;106:515-519. PMID:10460614
    [Medline]


  • Diez MJL, Li CY, Blanks PM.
    Blastic variant of hairy-cell leukaemia.
    Am J Clin Pathol 1987;87:576-583. PMID:3578132
    [Medline]


  • Doane LL, Ratain MJ, Golomb HM.
    Hairy cell leukaemia. Current management.
    Hematol Oncol Clin North Am 1990;4:489-502. PMID:2182604
    [Medline]


  • Else M et al.
    long remissions in hairy cell leukemia with purine analogs. A report of 219 patients with a median follow-up of 12.5 years.
    Cancer 2005;104:2442-2448. PMID:16245328
    [Medline]


  • Ewald O.
    Die leukämische Reticuloendotheliose.
    Deutsches Archiv für Klinische Medizin 1923;142:222-228.


  • Flandrin G et al.
    Treatment of hairy cell leukemia with recombinant alpha interferon: I. Quantitative study of bone marrow changes during the first months of treatment.
    Blood 1986;67:817-820. PMID:3947748
    [Medline]


  • Fietz T et al.
    Alemtuzumab (Campath-1H) in hairy cell leukemia relapsing after rituximab treatment.
    Hematol J 2004;5:451-452. PMID:15448675
    [Medline]


  • Filleul B et al.
    A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.
    Leukemia 1994;8:1153-1156. PMID:7913513
    [Medline]


  • Flinn IW et al.
    long-term follow-up of remission duration, mortality and second malignancies in hairy cell leukemia patients treated with pentostatin.
    Blood 2000;96:2981-2986. PMID:11049974
    [Medline]


  • Genini D et al.
    Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.
    Blood 2000;96:3537-3543. PMID:11071652
    [Medline]


  • Golumb HM et al., A Ramdomized study of duration of treatment with interferon alfa-2b in patients with hairy cell leukemia.
    J Natl Cancer Inst 1988;80:369-373. PMID:3282078
    [Medline]


  • Goodman GR, Beutler E, Saven A.
    Cladribine in the treatment of hairy cell leukaemia.
    Best Pract Res Clin Haematol 2003;16:101-116. PMID:12670469
    [Medline]


  • Goodman GR et al.
    Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
    J Clin Oncol 2003;21:891-896. PMID:12610190
    [Medline]


  • Gordon MS, Sosman JA.
    Clinical application of cytokines and biologic response modifiers.
    In: Hoffman R et al. (Eds).
    Hematology, basic principles and practice, 939-979.
    Churchill Livingstone, New York, Edinburgh, London, Philadelphia, 2000


  • Grever M et al.
    Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukaemia: an intergroup study.
    J Clin Oncol 1995;13:974-982. PMID:7707126
    [Medline]


  • Hagberg H.
    Chimeric monoclonal anti-CD20 antibody (rituximab) - an effective treatment for a patient with relapsing hairy cell leukaemia.
    Med Oncol 1999;16:221-222. PMID:10523804
    [Medline]


  • Hagberg H, Lundholm L.
    Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia.
    Br J Haematol 2001;115:609-611. PMID:11736943
    [Medline]


  • Hakimian D et al.
    Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukaemia.
    Blood 1993;82:1798-1802. PMID:7691237
    [Medline]


  • Hanson CA, Ward PC, Schnitzer B.
    A multilobular variant of hairy cell leukemia with morphologic similarities to T-cell lymphoma.
    Am J Surg Pathol 1989;13:671-679. PMID:2665535
    [Medline]


  • Harris NL et al.
    Lymphoma classification - from controvery to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms.
    Ann Oncol 2000;11 (Suppl 1):3-10. PMID:10707771
    [Medline]


  • Hoffman M, Auerbach L.
    Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine.
    Br J Haematol 2000;109:900-901. PMID:10970137
    [Medline]


  • Hoffmann MA et al.
    Treatment of hairy-cell leukaemia with cladribine: response, toxicity, and long-term follow-up.
    J Clin Oncol 1997;15:1138-1142. PMID:9060556
    [Medline]


  • Hounieu H et al.
    Hairy cell leukaemia. Diagnosis of bone marrow involvement in paraffin-embedded sections with monoclonal antibody DBA.44.
    Am J Clin Pathol 1992;98:26-33. PMID:1615922
    [Medline]


  • Jansen J, Hermans J.
    Clinical staging system for hairy cell leukemia.
    Blood 1982;60:571-577. PMID:7104487
    [Medline]


  • Johnston JB et al.
    The treatment of hairy cell leukemia with 2-deoxycoformycin.
    Br J Haematol 1986;63:525-534. PMID:3488071
    [Medline]


  • Johnston JB et al.
    Efficacy of 2-deoxycoformycin in hairy cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group.
    J Natl Cancer Inst 1988;80:765-769. PMID:3290498
    [Medline]


  • Juliusson G et al.
    Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukaemia.
    J Clin Oncol 1995;13:989-995. PMID:7707128
    [Medline]


  • Juliusson G, Liliemark J.
    Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2-deoxyadenosine (CdA): Relationship to opportunistic infections.
    Blood 1992;79:888-894. PMID:1346578
    [Medline]


  • Kamiguti AS et al.
    Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways.
    Oncogene 2003;22:2272-2284. PMID:12700663
    [Medline]


  • Katayama I et al.
    Hairy cell leukemia: a comparative study of Japanes and non-Japanese patients.
    Semin Oncol 1984;11 (Suppl 2):486-492. PMID: 6505710
    [Medline]


  • Kraut EH, Bouroncle BA, Grever MR.
    Pentostatin in the treatment of advanced hairy cell leukemia.
    J Clin Oncol 1989;7:168-172. PMID:2783731
    [Medline]


  • Kraut EH, Grever MR, Bouroncle BA.
    Long-term follow-up of patients with hairy cell leukemia after treatment with 2-deoxycoformycin.
    Blood 1994;84:4061-4063. PMID:7994024
    [Medline]


  • Kreitman RJ.
    Immunotoxins in cancer therapy.
    Curr Opin Immunol 1999;11:570-578. PMID:10508704
    [Medline]


  • Kreitman RJ.
    Immunological treatments of hairy-cell leukaemia.
    Best Pract Res Clin Haematol 2003;16:117-133. PMID:12670470
    [Medline]


  • Kreitman RJ et al.
    Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
    Blood 1999;94:3340-3348. PMID:10552943
    [Medline]


  • Kreitman RJ et al.
    Phase I trial of recombinant immunotoxin anti-Tac (Fv) PE38 (LMB-2) in patients with hematologic malignancies.
    J Clin Oncol 2000;18:1622-1636. PMID:10764422
    [Medline]


  • Kreitman RJ et al.
    Efficacy of the anti CD22 recombinant immunotoxin BL22 in chemotherapie resistant hairy cell leukemia.
    N Engl J Med 2001;345:241-247. PMID:11474661
    [Medline]


  • Kuppers R, Dalla-Favera R.
    Mechanisms of chromosomal translocations in B cell lymphomas.
    Oncogene 2001;20:5580-5594. PMID:11607811
    [Medline]


  • Kurzrock R et al.
    Second cancer risk in hairy cell leukemia: analysis of 350 patients.
    J Clin Oncol 1997;15:1803-1810. PMID:9164188
    [Medline]


  • Lauria F et al.
    Reduced hematological response to alpha-interferon therapy in patients with hairy cell leukemia showing a peculiar immunological phenotype.
    Cancer 1990;68:2233-2236. PMID:1693308
    [Medline]


  • Lauria F et al.
    Weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukaemia is effective and reduces infectious complications.
    Haematologica 1999;84:22-25. PMID:10091389
    [Medline]


  • Lauria F et al.
    Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.
    Haematologica 2001;86:1046-1050. PMID:11602410
    [Medline]


  • Liang J, Slingerland JM.
    Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.
    Cell Cycle 2003;2:339-345. PMID:12851486
    [Medline]


  • Matutes E et al.
    The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes.
    Leuk Lymphoma 1994a;14:57-61. PMID:7820054
    [Medline]


  • Matutes E et al.
    The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders.
    Blood 1994b;83:1558-1562. PMID:8123845
    [Medline]


  • Matutes E et al.
    The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study.
    Br J Haematol 1997;98:375-383. PMID:9266936
    [Medline]


  • Matutes E et al.
    The natural history and clinico-pathological features of the variant form of hairy cell leukemia.
    Leukemia 2001;15:184-186. PMID:11243388
    [Medline]


  • Matutes E, Wotherspoon A, Catovsky D.
    The variant form of hairy-cell leukaemia.
    Best Pract Res Clin Haematol2003;16:41-56. PMID:12670464
    [Medline]


  • Mey U et al.
    Advances in the treatment of hairy cell leukemia.
    Lancet Oncol 2003;4:86-94. PMID:12573350
    [Medline]


  • Nieva J, Bethel K, Saven A.
    Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukaemia.
    Blood 2003;102:810-813. PMID:12663446
    [Medline]


  • Nieva J, Saven A.
    Understanding hairy cell leukemia genetics.
    Leuk Lymphoma 2007;48:653-654. PMID:17454620
    [Medline]


  • Nicolaou F et al.
    CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD.
    Blood 2003;101:4033-4041. PMID:12576324
    [Medline]


  • Morton LM et al.
    Lymphoma incidence patterns by WHO subtype in the United States. 1992-2001.
    Blood 2006;107:265-76. PMID:16150940
    [Medline]


  • Pettitt AR.
    Mechanism of action of purine analogues in chronic lymphocytic leukemia.
    Br J Haematol 2003;121:692-702. PMID:12780783
    [Medline]


  • Pettitt AR, Zuzel M, Cawley JC.
    Hairy cell leukemia: biology and management.
    Br J Haematol 1999;106:2-8. PMID:10444156
    [Medline]


  • Piro LD et al.
    Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
    N Engl J Med 1990;322:1117-1121. PMID:1969613
    [Medline]


  • Piro LD, Ellison D, Saven A.
    The Scripps clinic experience with 2-chlorodeoxyadenosine in the treatment of heary cell leukemia.
    Leuk Lymphoma 1994;13:121-125. PMID:7820043
    [Medline]


  • Polliack A.
    Hairy cell leukemia: Biology, clinical diagnosis, unusual manifestations and assosiated disorders.
    Rev Clin Exp Hematol 2002;6:366-388. PMID:12823778
    [Medline]


  • Quesada JR et al.
    Alpha interferon for induction of remission in hairy cell leukemia.
    N Engl J Med 1984;310:15-18. PMID:6689734
    [Medline]


  • Quesada J et al.
    Treatment of hairy cell leukemia with recombinant a-interferon.
    Blood 1986;68:493-497. PMID:3730612
    [Medline]


  • Quigley MM et al.
    CD52 expression in hairy cell leukemia.
    Am J Hematol 2003;74:227-230. PMID:14635201
    [Medline]


  • Ratain MJ et al.
    Durability of responses to interferon alpha-2b in advanced hairy cell leukemia.
    Blood 1987;69:872-877. PMID:3814819
    [Medline]


  • Ratain MJ et al.
    Relapse after interferon-2b therapy for hairy cell leukemia. Analysis of prognostic variables.
    J Clin Oncol 1988;6:1714-1721. PMID:3054003
    [Medline]


  • Ravandi F et al.
    Eradication of minimal residual disease in hairy cell leukemia.
    Blood 2006;107:4658-4662. PMID:16497968
    [Medline]


  • Ribeiro P et al.
    Long-term outcome of patients with hairy cell leukemia treated with pentostatin.
    Cancer 1999;85:65-71. PMID:9921975
    [Medline]


  • Riccioni R, Galimberti S, Petrinin M.
    Hairy cell leukemia.
    Curr Treat Options Oncol2007;8:129-134. PMID:17926010
    [Medline]


  • Robak T.
    Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Biodrugs 2005;19:9-22. PMID:15691213
    [Medline]


  • Robak T.
    Current treatment options in hairy cell leukemia and hairy cell leukemia variant.
    Cancer Treat Rev 2006;32:365-376. PMID:16781083
    [Medline]


  • Robak T et al.
    Randomized comparison of weekly administration and daily courses of cladribine in patients with hairy cell leukemia. Updated results.
    Blood (ASH Annual Meeting Abstracts) 2004 104: Abstract 3478
    http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/3478


  • Rummel MJ.
    Haarzellenleukämie.
    In: Rummel MJ (Hrsg).
    NHL Diagnostik und Therapie, State of the Art, 205-219.
    Agileum, München, 2007


  • Sainati L et al.
    A variant form of hairy cell leukaemia resistant to alpha-interferon: clinical an phenotypic characteristics of 17 patients.
    Blood 1990;76:157-162. PMID:2364167
    [Medline]


  • Salomon-Nguyen F et al.
    The value of the monoclonal antibody, DBA44, in the diagnosis of B-lymphoid disorders.
    Leuk Res 1994;20:909-913. PMID:9009248
    [Medline]


  • Sansville JE et al.
    Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using concensus primer polymerase chain reaction for heavy chain gene.
    Am J Clin Pathol 2003;119:213-217. PMID:12579991
    [Medline]


  • Saven A et al.
    Longterm follow-up of patients with hairy cell leukaemia after cladribine treatment.
    Blood 1998;92:1918-1926. PMID:9731048
    [Medline]


  • Schrek R, Donnelly WJ.
    “Hairy” cells in blood in lymphoreticular neoplastic disease and “flagellated” cells of normal lymph nodes.
    Blood 1966;27:199-211. PMID:5322749
    [Medline]


  • Seymour JF et al.
    2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia.
    Blood 1994;83:2906-2911. PMID:7910051
    [Medline]


  • Seymour JF et al.
    Respone to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine.
    Leukemia 1995;9:929-932. PMID:7769859
    [Medline]


  • Seymour JF, Talpaz M, Kurzrock R.
    Response duration and recovery of CD4+ lymphocytes following deoxyformycin in interferon-a-resistant hairy cell leukemia: 7-year follow-up.
    Leukemia 1997;11:42-47. PMID:9001417
    [Medline]


  • Shurin SB.
    The spleen and its disorders.
    In: Hoffman R et al. (Eds).
    Hematology, basic principles and practice, 821-829.
    Churchill Livingstone, New York, Edinburgh, London, Philadelphia, 2000


  • Smalley RV et al.
    Splenectomy vs. alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia.
    Am J Hematol 1992;41:13-18. PMID:1503094
    [Medline]


  • Smith JW et al.
    Prolonged, continous treatment of hairy cell leukemia patients with recombinant interferon-alpha2a.
    Blood 1991;78:1664-1671. PMID:1912555
    [Medline]


  • Spiers ASD et al.
    Remissions in hairy cell leukemia with pentostatin (2’-deoxycoformycin).
    N Engl J Med 1987;316:825-830. PMID:2434850
    [Medline]


  • Steis RG et al.
    Resistance to recombinant interferon alfa-2a in hairy-cell leukaemia associated with neutralizing anti-interferon antibodies.
    N Engl J Med 1988;318:1409-1413. PMID:3367950
    [Medline]


  • Sun T et al.
    Hybrid form of hairy cell leukemia and chronic lymphocytic leukemia.
    Hematol Oncol 1990;8:283-294. PMID:1979043
    [Medline]


  • Swords R, Giles F.
    Hairy cell leukemia.
    Med Oncol 2007;24:7-15. PMID:17673807
    [Medline]


  • Tallman MS.
    Current treatment strategies for patients with hairy cell leukemia.
    Rev Clin Exp Hematol 2002;6:389-400. PMID:12823779
    [Medline]


  • Tallman MS et al.
    Relapse of hairy cell leukaemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience.
    Blood 1996;88:1954-1959. PMID:8822913
    [Medline]


  • Tallman MS et al.
    Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Clin Cancer Res 1999;5:1665-1670. PMID:10430066
    [Medline]


  • Thomas DA et al.
    Rituximab in relapsed or refractory hairy cell leukaemia.
    Blood 2003;102:3906-3911. PMID:12816862
    [Medline]


  • Tiacci E et al.
    Evolving concepts in the pathogenesis of hairy-cell leukaemia.
    Nat Rev Cancer 2006;6:437-448. PMID:16723990
    [Medline]


  • Troussard X, Flandrin G.
    Hairy cell leukemia. An update on a cohort of 93 patients treated in a single institution. Effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment.
    Leuk Lymphoma 1994;14:99-105. PMID:7820062
    [Medline]


  • Villernagne B et al.
    Two new cases of familial hairy cell leukemia associated with HLA haplotypes A2, B7, Bw4, Bw6.
    Leuk Lymphoma 2005;46:243-245. PMID:15621808
    [Medline]


  • von Rohr A et al.
    Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneos bolus injection: a phase II study.
    Ann Oncol 2002;13:1641-1649. PMID:12377655
    [Medline]


  • Westbrook CA, Golde DW.
    Autoimmune disease in hairy cell leukemia - clinical syndromes and treatment.
    Br J Hematol 1985;61:349-356. PMID:4041378
    [Medline]


  • Wheaton S et al.
    Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukaemia treated with 2-chlorodeoxyadenosine.
    Blood 1996;87:1556-1560. PMID:8608247
    [Medline]


  • Zakarijia A, Peterson LC, Tallman MS.
    Splenectomy and treatments of historical interest.
    Best Pract Res Clin Haematol 2003;16:57-68. PMID:12670465
    [Medline]


  • Zinzani PL et al.
    Efficacy of rituximab in hairy cell leukaemia treatment.
    J Clin Oncol 2000;18:3875-3877. PMID:11078503
    [Medline]


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"; Publikation als Buch: Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag [Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]